4.6 Article

NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing

Journal

THORAX
Volume 68, Issue 4, Pages 391-393

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2012-202376

Keywords

-

Funding

  1. Bayer PLC
  2. Sanofi Aventis
  3. GlaxoSmithKline
  4. Pfizer
  5. Novartis

Ask authors/readers for more resources

The National Institute for Health and Clinical Excellence recently published a clinical guideline on the management of venous thromboembolic disease and thrombophilia testing. Several stand-out recommendations are made which may be practice changing for many physicians, such as catheter-directed thrombolysis for ilio-femoral deep venous thrombosis, routine cancer screening and extended duration of anticoagulation for unprovoked events. In this article, we summarise the key points of the guideline and discuss remaining areas of controversy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available